Trisha Shetty

Carglumic acid

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
License data  EU EMA: Carbaglu
Routes of administration  Oral
Protein binding  Undetermined
CAS ID  1188-38-1
Pregnancy category  unknown
ATC code  A16AA05 (WHO)
Molar mass  190.2 g/mol
Bioavailability  30%
Carglumic acid
AHFS/  Consumer Drug Information

Carglumic acid uses reviews side effects and contraindications

Carglumic acid is an orphan drug, marketed by Orphan Europe under the trade name Carbaglu. Carglumic acid is used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. The initial daily dose ranges from 100 to 250 mg/kg, adjusted thereafter to maintain normal plasma levels of ammonia.


The US FDA approved it for treatment of hyperammonaemia on March 18, 2010. Orphan Drug exclusivity expires on March 18, 2017.

Adverse effects

The most common adverse effects include vomiting, abdominal pain, fever, and tonsillitis.


Carglumic acid Wikipedia

Similar Topics
The Opry House
Adele Addison
Yuma Nakayama